AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Merck & Co. Inc. MRK, -5.39% and AstraZeneca PLC AZN, -1.86% said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S. Food and Drug Administration. Lynparza's sNDA is for the adjuvant treatment of patients with BRCA-mutated, human epidermal growth factor receptor 2-negative high-risk early breast cancer who have already been treated with chemotherapy.

Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.

Covid vaccine makers' stocks soar on Omicron variant concerns

McDonald's

Both of these businesses could be in much better shape a year from now.

Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022

Novartis

Sanofi

U.S. investors often focus on owning domestic companies, as this is the region of the world they are likely most familiar with. As such, this can limit the number of quality stocks available to them for purchase.

A Trio of International Health Care Stocks for Income

A recent acquisition dinged this biopharma's bottom line, but is renewed growth right around the corner?

Bear of the Day: AstraZeneca (AZN)

Bristol-Myers

CVS Health

Patterson Companies

Needless to say, 2021 has been a banner year for equities, with the S&P 500 up a stunning 25%.

Top Strategist Says Health Care Could Rule in 2022: 5 Dividend Winners

AstraZeneca's boss said the new wave of coronavirus cases spreading throughout Europe was linked to the rejection of its Covid-19 vaccine by the EU. Speaking to the BBC, Pascal Soriot said that countries in Europe refusing to use the vaccine it developed with Oxford University might explain the explosion in infections seen recently in places such as Austria and the Netherlands.

AstraZeneca boss suggests Europe's Covid-19 spike linked to vaccine snub

Lackluster third-quarter results may have contributed to the decision to stop selling its COVID-19 vaccine at no profit.

AstraZeneca Decides It's OK to Make Money From the Pandemic

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of a technology company with those of a biopharmaceutical company, the two companies hope to advance drug discovery and

Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics

GlaxoSmithKline

Eli Lilly

Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.

Look to Big Pharma for Healthy Dividends

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) said new data from two COVID-19 Phase III trials has confirmed that its AZD7442 therapy provides protection against severe disease and death in high-risk populations. The trials showed that one 300mg IM dose of AZD7442, also called Evusheld, reduced the risk of symptomatic COVID-19 by 83% over six months, with no severe disease or deaths.

AstraZeneca preventative COVID-19 jab shown to cut risk of severe disease and death by over 80%

AstraZeneca Plc (NASDAQ: AZN) has shared new data from two Phase 3 trials of AZD7442, its long-acting antibody (LAAB) combination, in COVID-19 patients. In an analysis of the ongoing PROVENT trial evaluating a median of six months of participant follow-up, one 300mg intramuscular (IM) dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% compared to placebo.

AstraZeneca's COVID-19 Antibody Shows 83% Protection Over Six Months

When administered to individuals who hadn't been exposed to Covid-19, the drug completely eliminated the risk of severe disease or death, the drugmaker said.

AstraZeneca's Antibody Cocktail Is 83% Effective At Preventing Covid-19 Symptoms After Six Months, Trial Shows

AstraZeneca's antibody treatment has been shown to be highly effective at preventing Covid in people who may not respond well to vaccines.

AstraZeneca's antibody drug over 80% effective at preventing Covid, trial shows

AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.

Dow Jones Newswires: AstraZeneca: Studies show antibody reduces COVID risk

AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.

AstraZeneca (AZN), Moderna's Heart Failure Study Successful

Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting (CABG). AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A).

AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure

Amazon

Bayer AG

Alphabet

Recursion Pharmaceuticals

Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are too complex for humans to discern.

Artificial Intelligence In Drug Discovery

Salesforce

Wells Fargo

Xilinx

Jeremy Grantham (Trades, Portfolio)'s GMO LLC recently disclosed its 13F portfolio updates for the third quarter of 2021, which ended on Sept. 30.

Jeremy Grantham's Firm Profits From Wave of Acquisitions in 3rd Quarter

The drugmaker announced disappointing third-quarter earnings results.

Why AstraZeneca Stock Is Sinking Today

AstraZeneca PLC (AZN) CEO Pascal Soriot on Q3 2021 Results - Earnings Call Transcript

AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.

AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down

Shares of AstraZeneca plc (LON: AZN) are down about 5.0% on Friday after the pharmaceutical giant said the cost of developing its COVID-19 vaccine swung it to a net loss in the fiscal third quarter. Q3 financial results AstraZeneca reported $1.65 billion in net loss – a massive downturn from $651 million it posted in […] The post AstraZeneca blames COVID-19 vaccine for Q3 loss appeared first on Invezz.

AstraZeneca blames COVID-19 vaccine for Q3 loss

AstraZeneca (NASDAQ:AZN) reported its Q3 earnings results on Friday, November 12, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: AstraZeneca Q3 Earnings

News for AstraZeneca Stock (AZN)